lifestyle.massnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
GRIT BIOTECHNOLOGY
Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million
April 29, 2026
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin’s Lymphoma at the 2025 ASH Annual Meeting
December 7, 2025
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
November 6, 2025